Henderson Group Plc Janus H... Net Worth

The estimated Net Worth of Henderson Group Plc Janus H... is at least $5.08 Milhão dollars as of 16 August 2024. Henderson H owns over 5,818 units of ARCA biopharma Inc stock worth over $5,081,311 and over the last few years Henderson sold ABIO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Henderson H ABIO stock SEC Form 4 insiders trading

Henderson has made over 3 trades of the ARCA biopharma Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Henderson bought 5,818 units of ABIO stock worth $17,047 on 16 August 2024.

The largest trade Henderson's ever made was buying 408,777 units of ARCA biopharma Inc stock on 2 July 2024 worth over $1,426,632. On average, Henderson trades about 211,559 units every 15 days since 2024. As of 16 August 2024 Henderson still owns at least 2,117,213 units of ARCA biopharma Inc stock.

You can see the complete history of Henderson H stock trades at the bottom of the page.

What's Henderson H's mailing address?

Henderson's mailing address filed with the SEC is 201 BISHOPGATE201 BISHOPGATE, , LONDONLONDON, X0X0, EC2M 3AEEC2M 3AE.

Insiders trading at ARCA biopharma Inc

Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.

What does ARCA biopharma Inc do?

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.

Complete history of Henderson H stock trades at ARCA biopharma Inc

ARCA biopharma Inc executives and stock owners

ARCA biopharma Inc executives and other stock owners filed with the SEC include:

• Michael Bristow,
  President, Chief Executive Officer, Director
• Dr. Michael R. Bristow M.D., Ph.D.,
  Co-Founder, Pres, CEO & Director
• Thomas A. Keuer,
  Chief Operating Officer
• Christopher Ozeroff,
  Senior Vice President, General Counsel, Secretary
• Christopher D. Ozeroff,
  Sr. VP, Gen. Counsel & Sec.
• Raymond Woosley,
  Director
• Daniel Mitchell,
  Director
• Anders Hove,
  Director
• Linda Grais,
  Lead Independent Director
• Brian Selby,
  Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
• Thomas Keuer,
  Chief Operating Officer
• Robert Conway,
  Chairman of the Board
• Dr. Debra Marshall FACC, M.D.,
  Chief Medical Officer
• C. Jeffrey Dekker,
  Chief Financial Officer
• Henderson Group Plc Janus H...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Healthcare Capital Partners...,
  
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• Equity Opportunities Fund I...,
  
• Jean Francois Formela,
  Director
• Kathryn E Falberg,
  CFO and COO
• J William Freytag,
  Director
• Mary K Pendergast,
  Director
• Patrick M Wheeler,
  acting Chief Financial Officer
• Riley Mccormack,
  10% owner
• David George Lowe,
  Director
• Burton E Sobel,
  Director
• Venture Fund Vii L P Atlas,
  10% owner
• Richard B Brewer,
  Director
• John L Zabriskie,
  Director
• Venture Partners Qualified ...,
  10% owner
• Ted W Love,
  Director
• Funds, Lp Ma Weaver Jacob F...,
  
• Jacob Ma Weaver,
  
• Fund, Lp Funicular,
  
• C. Jeffrey Dekker,
  Chief Financial Officer
• Fund, Lp Ma Weaver Jacob Fu...,
  
• Funds, Lp Funicular,
  10% owner
• James P Flynn,
  Director